Navigation Links
Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
Date:11/21/2007

SAN DIEGO, Nov. 21 /PRNewswire-FirstCall/ -- Alliance Pharmaceutical Corp. (OTC Bulletin Board: ALLP). Following a Steering Committee meeting last week in China with its partner Beijing Double-Crane Pharmaceutical Co., Ltd. (Double-Crane), Alliance has updated its clinical development plan for Oxygent(TM) (perfluorochemical [PFC] emulsion) to focus primarily on supporting the initial clinical development of Oxygent in China. The clinical development plan for China is to investigate Oxygent in maintaining hemodynamic stability during major surgery, thereby potentially reducing or avoiding intraoperative transfusions of donor blood in major surgery. In addition, the Phase 2 clinical trial in China will incorporate oxygenation endpoints of postoperative improvement of organ function, such as the gut, heart, brain and kidney. As a result, Alliance will discontinue enrollment in the current French study and evaluate a new protocol to correspond to the China Phase 2 study. Alliance is currently transferring the manufacturing technology to enable Double-Crane to manufacture Oxygent in China. Following the manufacture of clinical supplies in China, Double-Crane plans to submit an IND to the sFDA, which is anticipated to be completed in 2008. Alliance will seek additional funding to support this plan.

About Alliance Pharmaceutical Corp.

Alliance is a development-stage pharmaceutical company that is currently focused on developing its lead product, Oxygent, which is based on its proprietary PFC technology. Oxygent is being developed as an intravascular oxygen carrier designed to augment oxygen delivery in surgical patients.

Except for historical information, the matters set forth in this release are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth herein. Alliance refers you to cautionary information contained in documents Alliance files with the Securit
'/>"/>

SOURCE Alliance Pharmaceutical Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015 A lot of discussion in ... for treating  certain illnesses, injuries, or conditions. As medical science ... treatment methods with ones that they consider to be more ... is not one textbook method of treatment that stands out ...
(Date:1/23/2015)... Jan. 23, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO ... therapies for operable and inoperable solid tumor cancers, announced today ... 7 th Annual Phacilitate Immunotherapy Forum in ... Phacilitate will take place on January 26 at 10:30 a.m. ...
(Date:1/23/2015)... , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( ... of directors of Advaxis, Inc. ("Advaxis" or the "Company") ... has breached its fiduciary duties to shareholders. ... an investing website reporting that Advaxis had misrepresented the ...
Breaking Medicine Technology:No One-Size-Fits-All Remedy for Hernia Correction 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2
... Feb. 10 Amira Pharmaceuticals, Inc. announced today ... Flavia V. Castelino , M.D. of Massachusetts General Hospital, ... which demonstrates that the bioactive lipid lysophosphatidic acid (LPA), through ... fibrogenesis in the bleomycin mouse model of scleroderma.  Data will ...
... OXFORD, England , February 10 ... the needle-free administration of solid,dose therapeutics and vaccines, today ... ( $4.3 million ) investment round. The,fundraising was ... including Hygea VCT and Oxford Technology VCTs. The company ...
Cached Medicine Technology:Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma 2Glide Pharma Completes Oversubscribed GBP2.7 Million ($4.3 Million) Investment Round 2Glide Pharma Completes Oversubscribed GBP2.7 Million ($4.3 Million) Investment Round 3
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of ... area has treated just about every type of injury that can ... for those same twenty-plus years, the team at Doctors on ... the best possible doctor. With the combined breadth of ...
(Date:1/22/2015)... 2015 Joan Lunden, award-winning American journalist, ... the upcoming 32nd Annual Miami Breast Cancer Conference ... Resource®, LLC (PER®) , shares that “a fast-growing, virulent” ... if she had not followed up her clean mammogram ...
(Date:1/22/2015)... 22, 2015 Yesterday, Senator Holly ... and Kristin Olsen (R-Modesto) were honored by the ... advancing biotechnology, biomedical science, medical device and pharmaceutical ... received the “2014 Life Sciences Champion” award from ...
(Date:1/22/2015)... Florida (PRWEB) January 22, 2015 IsoComforter, Inc. ... therapy machine with patented IsoTube design to treat specific body ... introduced the most progressive and easy to use patented cold ... post-operative and sports related orthopedic and muscle injuries. IsoComforter ...
(Date:1/22/2015)... January 22, 2015 Payday lending practices ... communities and cause financial distress to the states that ... at Howard University’s Center on Race and Wealth. , ... economic activity, payday loans at the same time substantially ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2
... doctors say sunitinib,s benefits outweigh its risks , , WEDNESDAY, ... sunitinib (Sutent) can cause high blood pressure in patients ... echoes the results of a study published last month ... risk of heart failure among patients with stomach cancer. ...
... Mich. One in four Americans in the hospital right ... get a urinary tract infection from that catheter. All of ... , And with every new case, UTIs will retain ... percent of infections related to hospitalization. , But despite ...
... University of California, San Francisco are reporting significant results ... the safe removal of tumors near language pathways in ... reduces the amount of time a patient must be ... study provides new data that refines scientists understanding of ...
... a non-invasive way to determine the existence and extent ... of pharmacologic strategies to combat the condition. These findings ... published by John Wiley & Sons on behalf of ... (AASLD). The article is also available online at Wiley ...
... most common cause of disability in the United States. ... continues to age, the toll of this disease will escalate. ... burden and its impact on our nations health care and ... by any form of arthritisis critical. , The National Arthritis ...
... of chemicals in red wine grapes may significantly reduce ... a study published recently in the Journal of Agricultural ... present in large amounts in fermented seeds and skins ... ability of bacteria to contribute to tooth decay. Beyond ...
Cached Medicine News:Health News:New Cancer Drug Boosts Blood Pressure 2Health News:New Cancer Drug Boosts Blood Pressure 3Health News:Catheter chaos: Hospitals lag in preventing common infection 2Health News:Catheter chaos: Hospitals lag in preventing common infection 3Health News:Catheter chaos: Hospitals lag in preventing common infection 4Health News:Language centers revealed, brain surgery refined with new mapping 2Health News:Language centers revealed, brain surgery refined with new mapping 3Health News:MRI techniques evolving towards better assessment of liver fibrosis 2Health News:The prevalence and impact of arthritis and other rheumatic conditions in the United States 2Health News:The prevalence and impact of arthritis and other rheumatic conditions in the United States 3Health News:Winemaking waste proves effective against disease-causing bacteria in early studies 2Health News:Winemaking waste proves effective against disease-causing bacteria in early studies 3Health News:Winemaking waste proves effective against disease-causing bacteria in early studies 4
... enzyme immunoassays, designed to meet the working ... allows the user to run set assays ... floating manifold on this strip washer adjusts ... a time. Reliable, compact, and self-contained, offers ...
... miniGene LW is a new plate washing system ... and 384 channel microplates with flat, V-shaped or ... 8 or 16 channel nozzle heads. Simple LCD ... An optional plate stacker is available for the ...
... to 8000 L/day of Type III Laboratory-grade ... to produce up to 8000 L/day of ... feedwater., One Complete Purification and Control Unit, ... centralized system, providing total control of all ...
... Up to 8000 L/day of Type III ... designed to produce up to 8000 L/day ... tap feedwater., One Complete Purification and Control ... a centralized system, providing total control of ...
Medicine Products: